This mutational analysis will be very important, given the fact that integrated biomarker-based trials represent the most likely strategy to fully realize the potential therapeutic efficacy of targeted therapy in gynecological cancer with less frequency of alterations in the KRAS pathway. The gene discussed is KRAS; the disease is female reproductive organ cancer.